ICU SEASTAR MEDICAL HOLDING CORPORATION

SeaStar Medical to Present at Noble Capital Markets’ NobleCon20 on December 4, 2024

SeaStar Medical to Present at Noble Capital Markets’ NobleCon20 on December 4, 2024

DENVER, Nov. 26, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that management will present a company overview at , ’ 20th Annual Emerging Growth Equity Conference, on Wednesday, December 4 at 12:00 p.m. Eastern time (9:00 a.m. Pacific time). The conference is being held in Boca Raton, Fla.

A webcast of the presentation will be available beginning December 5 on the Company and will be archived for 90 days.

About SeaStar Medical

SeaStar Medical is a commercial-stage medical technology company that is redefining how extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs. SeaStar Medical’s novel technologies rely on science and innovation to provide life-saving solutions to critically ill patients. The Company is developing and commercializing cell-directed extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. For more information visit or visit us on or .

Contact:

Alliance Advisors IR

Jody Cain

(310) 691-7100

# # #



EN
26/11/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on SEASTAR MEDICAL HOLDING CORPORATION

 PRESS RELEASE

SeaStar Medical Grows Customer Base and Expands QUELIMMUNE Surveillanc...

SeaStar Medical Grows Customer Base and Expands QUELIMMUNE Surveillance Registry Highest Rated Children’s Medical Centers Now Employ QUELIMMUNE for Ultra-Rare Cases of Pediatric AKI HDE Surveillance Registry Data Captures Key Metrics for Future Analysis of QUELIMMUNE Performance DENVER, July 16, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company announced today that it has added a nationally-recognized, Texas-based children’s hospital to its growing customer base of QUELIMMUNE therapy users. The was approved by the U.S. Fo...

 PRESS RELEASE

SeaStar Medical Announces $4 Million Registered Direct Offering Priced...

SeaStar Medical Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules DENVER, July 10, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, today announced it has entered into a definitive agreement for the issuance and sale of an aggregate of 5,242,464 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $0.763 per share of common stock (or p...

 PRESS RELEASE

SeaStar Medical Expands QUELIMMUNE Adoption for Critically Ill Pediatr...

SeaStar Medical Expands QUELIMMUNE Adoption for Critically Ill Pediatric Patients with Acute Kidney Injury (AKI) Nationally Recognized Texas Children’s Hospital Adds First-In-Class Therapy as a Potential Life-Saving Treatment in Ultra-Rare Cases of Pediatric AKI DENVER, July 08, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today that the QUELIMMUNE therapy has been adopted for use by the nationally r...

 PRESS RELEASE

SeaStar Medical Announces Positive Nasdaq Listing Determination

SeaStar Medical Announces Positive Nasdaq Listing Determination DENVER, July 02, 2025 (GLOBE NEWSWIRE) -- Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that it has received confirmation from The Nasdaq Stock Market that the Company has evidenced compliance with the minimum $2.5 million stockholders’ equity requirement and all other applicable criteria for continued listing on The Nasdaq Capital Market. Accordingly, the previousl...

 PRESS RELEASE

SeaStar Medical Reports Update on Nasdaq Listing Status

SeaStar Medical Reports Update on Nasdaq Listing Status DENVER, June 25, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life announced today that it has undertaken a series of transactions to ensure compliance with Nasdaq’s continued listing standards.   Last year on June 24, 2024, SeaStar Medical received a written notification from Nasdaq’s Listing Qualifications Staff that it was not in compliance with the requireme...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch